P-012: Cevostamab is efficacious and well tolerated in patients aged < 65 and ≥65 years with relapsed/refractory multiple myeloma (RRMM)
Title:
P-012: Cevostamab is efficacious and well tolerated in patients aged < 65 and ≥65 years with relapsed/refractory multiple myeloma (RRMM)
Author:
Krishnan, Amrita Cohen, Adam Trudel, Suzanne Spencer, Andrew Lesokhin, Alexander Wong, Chihunt Choeurng, Voleak Cooper, James Sumiyoshi, Teiko Goodman, Grant Jin, Hyun Yong Sheikh, Semira Harrison, Simon